Showing posts with label treatment. Show all posts
Showing posts with label treatment. Show all posts

Wednesday, August 6, 2014

Black market for "lifesaving HIV treatments"

The Washington Post

Watchdog: Some Medicare spending on HIV drugs appear questionable in 2012 audit 
By Charles Ornstein

"Medicare spent more than $30 million in 2012 on questionable HIV medication costs, the inspector general of the Department of Health and Human Services said in a report set for release Wednesday.

The report offers a litany of possible fraud schemes, all paid for by Medicare’s prescription drug program known as Part D."

 Medicare paid over $30 million in fraud schemes to thieves re-sell the "lifesaving treatments."  

The only thing missed is that every penny Medicare, Medicaid, ADAP, the VA, etc pays for "ARVs" is a gigantic fraud for worthless, dangeorus toxic chemotherapy.--Terry Michael

In Detroit, a 77-year-old woman purportedly filled $33,500 worth of prescriptions for 10 different HIV medications. But there’s no record that she had HIV or that she had visited the doctors who wrote the scripts.

A 48-year-old in Miami went to 28 pharmacies to pick up HIV drugs worth nearly $200,000, almost 10 times what average patients get in a year. The prescriptions were supposedly written by 16 health providers.

And on a single day, a third patient received $17,500 worth of HIV drugs ­ and none the rest of the year. She acquired more than twice the recommended dose of five HIV drug ingredients.

Monday, July 2, 2012

Four-in-one Aids drug gets green light


Paris - An experimental once-daily pill that combines four drugs to fight HIV is as safe and effective as commonly-prescribed treatments against the Aids virus, researchers reported in The Lancet on Friday.
Doctors tested the new drug, called Quad, for the third and final phase in which new pharmaceutical products are vetted for safety and effectiveness.
Publication in the British journal follows a recommendation in May by a US Food and Drug Administration (FDA) advisory panel to approve Quad for previously untreated adults infected with HIV-1. A final decision is expected by August.
The first trial entailed testing Quad against a three-in-one pill, Atripla, which since 2006 has been a standard treatment for the human immunodeficiency virus (HIV).

Tuesday, November 1, 2011

An HIV Drug Delivery Patch in the Pipeline


GET DRUGS in your system faster!

ImQuest Biosciences, based in Frederick, Maryland, is developing a skin patch to deliver antiretroviral medications, according to a presentation at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition being held October 23 through 27 in Washington, DC. Though the patch is in very early stages of development—it has not yet been studied in animals, let alone humans—it holds great promise for people living with HIV, the researchers suggest.